Urgent Care Now Open

Open daily. Walk in or reserve an appointment today. Learn more

Heart and Vascular Clinical Trials

Doylestown Health Medical Research

The following trials are coordinated by the Doylestown Health Medical Research Department. For more information, please call 215-345-2119.

Active Trials - Open to Enrollment:

Paroxysmal or persistent atrial fibrillation with high blood pressure - SYMPLICITY AF

  • To evaluate the feasibility of performing both renal artery denervation and pulmonary vein isolation on the same patient to characterize both safety and effectiveness in patients with high blood pressure who have paroxysmal (occasional episodes) or persistent (lasting more than seven days) atrial fibrillation.
  • Open to enrollment

Narrowing of Carotid Artery (asymptomatic) - CREST-2

  • Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
  • An NIH study for patients who have significant narrowing of the carotid artery who have not experienced stroke symptoms (asymptomatic)
  • This four-year study includes close monitoring and intense medical management to reduce stroke risk factors including control of high blood pressure, cholesterol, diabetes, smoking cessation, diet and exercise. The study compares carotid endarterectomy (CEA) with medical management vs carotid stenting (CAS) with medical management vs just medical management
  • Open to enrollment

CREST-2 Registry

  • A companion study to the CREST-2 trail offering CREST-2 approved and conditional approved interventionists an opportunity to expand their expertise in performing CAS so they can fully participate in C2
  • All eligible CAS cases performed by study interventionists are registered so they can be reviewed
  • Open to enrollment

Upcoming Trials - Not Yet Enrolling:

TAVR and Atrial Fibrillation – ENVISAGE-TAVI AF

  • Edoxaban (a new, oral anticoagulant) Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients with Atrial Fibrillation
  • Patients will be followed for 3 years

Coronary Artery Disease - PIONEER III

  • Trial to Assess Safety and Efficacy of a new stent platform for drug eluting stents for the coronary arteries
  • Patients will be followed for 5 years

Active Trials - Not Accepting New Patients:

Coronary Artery Disease - ABSORB III & IV

  • Enrolled patients in follow up through September 2021

Coronary Artery Disease – BIONICS

  • Enrolled patients in follow up through August 202

Coronary Artery Disease – PROMUS

  • Enrolled patients in follow up through April 2018

Heart Attack- ARTEMIS

  • Enrolled patients in follow up through December 2017

Peripheral Artery Disease - MIMICS-2

  • Enrolled patients in follow up through June 2019

Doylestown Health Cardiology - West State Street Office

The following trials are coordinated by Doylestown Health Cardiology, located at 315 W. State Street, Doylestown, PA. For more information, contact Mary O. Bongarzone, MSN, RN, clinical research coordinator, at 215-345-1900.

Active Trials - Open to Enrollment:

Dal-Gene: (Dal Cor Pharmaceuticals)

  • Evaluate the effects of dalcetrapib (CETP inhibitor) that raises good cholesterol (HDL)
  • Inclusion: MI/ACS in the last 4-12 weeks
  • Must have specific (AA) genotype to be enrolled – Tested at enrollment
  • Open to enrollment

CIRT: (NHLBI)

  • Evaluate the effectiveness of low dose methotrexate in the prevention of recurrent cardiovascular events among stable post MI or multivessel CAD patients with T2DM or Metabolic Syndrome
  • Open to enrollment

GOULD: (Amgen)

  • Evaluation of the treatment of hypercholesterolemia by observation (REGISTRY ONLY) of subjects with ASCVD receiving lipid lowering therapy.
  • Are patients with CHD achieving recommended LDL levels? If not, why?
  • Retrospective medical record review and telephone surveys EVERY 6 MONTHS.
  • Open to enrollment

VICTORIA: (Merck)

  • A clinical outcomes trial of efficacy and safety of the oral sGC stimulator Vericiguat in patients with heart failure and reduced ejection fraction (HFrEF).
  • Inclusion: NYHA Class II-IV HF; Symptomatic/treated for acute heart failure within the last 3 months. Ejection fraction <45%
  • Open to enrollment

For more information about Doylestown Health's open trials visit the U.S. National Institutes of Health's Clinical Trials database.

Learn More

Show more Show less